|
4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- Suppliers list
|
|
| | 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- Basic information |
| Product Name: | 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- | | Synonyms: | 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)-;1-Palmitoyl-2-Docosahexaenoyl-sn-glycero-3-PE;1-Palmitoyl-2-Docosahexenoyl-sn-Glycero-3-Phosphatidylethanolamine;4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester | | CAS: | 96998-00-4 | | MF: | C43H74NO8P | | MW: | 764.02 | | EINECS: | | | Product Categories: | | | Mol File: | 96998-00-4.mol | ![4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- Structure](CAS/20200331/GIF/96998-00-4.gif) |
| | 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- Chemical Properties |
| Boiling point | 775.3±70.0 °C(Predicted) | | density | 1.024±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Chloroform: 10 mg/ml | | form | liquid | | pka | 1.17±0.50(Predicted) | | InChIKey | MPWUZHVZZKSTPV-MADBQMNMSA-N | | SMILES | [H][C@@](COP([O-])(OCC[NH3+])=O)(OC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)COC(CCCCCCCCCCCCCCC)=O |
| WGK Germany | WGK 3 | | Storage Class | 6.1D - Non-combustible acute toxic Cat.3 toxic hazardous materials or hazardous materials causing chronic effects | | Hazard Classifications | Acute Tox. 3 Inhalation Acute Tox. 4 Oral Aquatic Chronic 3 Carc. 2 Eye Irrit. 2 Repr. 2 Skin Irrit. 2 STOT RE 1 STOT SE 3 |
| | 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- Usage And Synthesis |
| Uses | 1-Palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine is used in the mRNA combination therapy for treatment of cancer. | | Definition | ChEBI: 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine zwitterion is a phosphatidylethanolamine 38:6 zwitterion in which the acyl substituents at positions 1 and 2 are specified as hexadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively. It is a tautomer of a 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine. |
| | 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- Preparation Products And Raw materials |
|